Ovid Therapeutics Inc. (NASDAQ: OVID) is a Healthcare company (Biotechnology) with a market capitalization of $419M. The Maz Rating grades it against the other companies in its sector.
Ovid Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.22, Ovid Therapeutics Inc. trades at 284.9x sales and 2.2x book value. Over the last twelve months it generated about $1M of revenue and a net loss of $34M. It runs an operating margin of -4700.3% and a net margin of -2971.3%. It shows return on equity of -23.4%, return on invested capital of -32.2% and a free cash flow yield of -13.8%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 11.97. Over the past 52 weeks the share price ranged from $1.21 to $3.11, with a beta of 0.24.
Ovid Therapeutics Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 11 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Ovid Therapeutics Inc. (OVID) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global and Dow Jones, and fails AAOIFI, MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 39.2% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 26.2% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 26.2% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.18% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 57.7% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 61.5% / 33.33% · (Cash+Recv) / Total Assets 61.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Ovid Therapeutics Inc. (OVID) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global and Dow Jones, and fails AAOIFI, MSCI and FTSE.
No. Ovid Therapeutics Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Ovid Therapeutics Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.